Lookup NU author(s): Vic Hart, Dr Hannah Gautrey, Josh Kirby, Professor Alison Tyson-Capper
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2020 Hart et al.Overexpression of the HER2 receptor occurs in approximately 20% of breast cancer patients. HER2 positivity is associated with poor prognosis and aggressive tumour phenotypes, which led to rapid progress in HER2 targeted therapeutics and diagnostic testing. Whilst these advances have greatly increased patients’ chances of survival, resistance to HER2 targeted therapies, be that intrinsic or acquired, remains a problem. Different forms of the HER2 protein exist within tumours in tandem and can display altered biological activities. Interest in HER2 variants in breast cancer increased when links between resistance to anti-HER2 therapies and a particular variant, ∆16-HER2, were identified. Moreover, the P100 variant potentially reduces the efficacy of the anti-HER2 therapy trastuzumab. Another variant, Herstatin, exhibits ‘auto-inhibitory’ behaviour. More recently, new HER2 variants have been identified and are currently being assessed for their pro- and anti-cancer properties. It is important when directing the care of patients to consider HER2 variants collectively. This review considers HER2 variants in the context of the tumour environment where multiple variants are co-expressed at altered ratios. This study also provides an up to date account of the landscape of HER2 variants and links this to patterns of resistance against HER2 therapies and treatment plans.
Author(s): Hart V, Gautrey H, Kirby J, Tyson-Capper A
Publication type: Article
Publication status: Published
Journal: Oncotarget
Year: 2020
Volume: 11
Issue: 46
Pages: 4338-4357
Online publication date: 17/11/2020
Acceptance date: 10/10/2020
ISSN (electronic): 1949-2553
Publisher: Impact Journals LLC
URL: https://doi.org/10.18632/oncotarget.27789
DOI: 10.18632/ONCOTARGET.27789
Altmetrics provided by Altmetric
